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Abstract The interaction of T-lymphocytes expressing the
CD40 ligand (CD154) and cells of the vessel wall expressing
the corresponding receptor protein (CD40) may play an
important role in chronic inflammation including arteriosclerosis.
One way of interfering with CD40-CD154 signalling is to
prevent CD40 expression, the regulation of which, however, has
yet to be elucidated. Therefore, we studied CD40 expression in
rat aortic cultured smooth muscle cells. Both CD40 mRNA and
protein expression in these cells was markedly enhanced as early
as 6 h after exposure to different pro-inflammatory cytokines.
Experiments with actinomycin D and subsequent run-on analyses
revealed that CD40 expression in response to these cytokines was
regulated at the level of transcription. Moreover, electrophoretic
mobility shift analyses along with the employment of transcrip-
tion factor decoy oligodeoxynucleotides demonstrated that tumor
necrosis factor K via nuclear UB and interferon-Q via signal
transducer and activator of transcription-1 up-regulate CD40
gene expression in rat aortic cultured smooth muscle cells.
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1. Introduction
Initially identi¢ed as a B-cell surface antigen, CD40 is now
considered as a member of the nerve growth factor/tumor
necrosis factor (TNF) receptor family [1^3]. In addition to
antigen-presenting cells, expression of CD40 has also been
documented for a variety of non-immune cells including en-
dothelial cells, ¢broblasts and vascular smooth muscle cells
[4]. The ligand for CD40 (CD154) is a membrane-bound
member of the TNF gene family [2,3] that is expressed by
activated CD4 T-cells, mast cells, activated platelets [5] and
possibly also in endothelial cells at sites of in£ammation [4].
CD40-CD154 interactions play a crucial role not only in
humoral and cellular immunity, but also in T-cell-mediated
in£ammatory responses [1^3]. Thus, activation of circulating
monocytes by CD154 enhances their expression of pro-in£am-
matory cytokines, adhesion molecules and MHC class II anti-
gen [6]. In endothelial cells, CD154 up-regulates the expres-
sion of integrins and chemokines and, as a consequence,
enhances the recruitment and extravasation of circulating
monocytes [7,8]. Activated monocytes and endothelial cells,
on the other hand, augment the expression of CD154 on
CD4 T-cells [9].
It does not come as a surprise, therefore, that the CD40-
CD154-mediated interaction between endothelial cells, acti-
vated T-cells and circulating monocytes has been suggested
to play an important role in the pathogenesis of various auto-
immune diseases [1^3] as well as in cardiac allograft rejection
[10] and arteriosclerosis [11,12]. Thus far, no antagonists for
CD40 are known and there are no reports regarding the reg-
ulation of CD40 expression in CD154 target cells. Indeed,
only part of the promoter region of the human CD40 gene
has been sequenced, but not yet characterized in detail [13], so
that it is not known which transcription factors regulate
CD40 expression. We hypothesized that by elucidating these
regulatory mechanisms, one may devise a strategy (i.e. down-
regulation of CD40 expression in CD154 target cells) for ther-
apeutically interfering with CD40-CD154 signalling in the
afore-mentioned pathophysiological conditions. Endothelial
and smooth muscle cells are the main target cells for activated
T-cells in the vessel wall, especially in arteriosclerosis. There-
fore, we have investigated in detail the cytokine-inducible ex-
pression of CD40 in cultured smooth muscle cells of the rat
aorta (raSMC).
2. Materials and methods
2.1. Cell culture
Smooth muscle cells were isolated from the rat aorta by the explant
technique. Aortae (1.5 mm in diameter) were isolated from pentobar-
bitone-anesthetized male Wistar rats (250^300 g body weight), cleaned
under sterile conditions of adherent fat and connective tissue and cut
open longitudinally. The endothelium was scraped o¡ with a razor
blade, the adventitia removed by using small forceps and the remain-
der of the blood vessel was cut into segments of approximately 3 mm
width. These were incubated in non-coated six well plates in 1 ml
Waymouth medium (Gibco BRL, Paisly, UK via Life Technologies
GmbH, Karlsruhe, Germany) containing 10% FBS, 50 U/ml penicil-
lin, 50 Wg/ml streptomycin, 10 U/ml nystatin, 5 mmol/l HEPES and
5 mmol/l TES until there was a visible outgrowth of cells (usually
within less than 1 week). Thereafter, the segments were removed
and the culture medium exchanged every 2 days for approximately
1 week until the cells reached con£uence. They were harvested by
using 0.05% (w/v) trypsin and 0.02% (w/v) EDTA, pooled and seeded
at a ratio of 1:5 into 100 mm diameter Petri dishes. Cells for the
experiments described were derived from passages 2^4 of individual
preparations. They were identi¢ed after ¢xation with p-formaldehyde
by positive immunostaining for smooth muscle K-actin with a mono-
clonal anti-K-smooth muscle actin clone from mouse ascites (dilution
1:1000, Sigma-Aldrich, Deisenhofen, Germany), a secondary anti-
mouse IgG-FITC conjugate from sheep (dilution 1:60, Sigma-Al-
drich) and visualization of the actin ¢bers by confocal laser scanning
microscopy (Leica Microsystems, Heidelberg, Germany). According
to this procedure, the cultured raSMC appeared to be essentially
homogenous and free of ¢broblasts.
All incubation were performed in Waymouth medium containing
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10% FBS with smooth muscle cells grown to s 80% con£uence either
in six well plates (1.5U106 cells/well) for reverse transcription (RT)-
PCR analyses or in 60 mm diameter Petri dishes (5U106 cells/dish) for
electrophoretic mobility shift analyses (EMSA) and Western blot
analyses. Incubations were terminated by rinsing the cells with Hank’s
balanced salt solution followed by mRNA or protein extraction. The
cell viability was assessed at the light microscope level as well as by
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) cytotoxicity assay [14] and found to be largely una¡ected by
any of the test compounds studied.
2.2. RT-PCR analysis
The cultured cells were lysed with guanidinium thiocyanate (GTC)
bu¡er (Qiagen, Hilden, Germany) and total RNA was extracted with
the Qiagen RNeasy kit. First strand cDNA synthesis from 3 Wg of
total RNA was performed with Superscript reverse transcriptase (Life
Technologies) according to the manufacturer’s instructions. To nor-
malize the cDNA amount in the samples, 2.5% of the resulting cDNA
was used for PCR analysis of the house keeping genes, elongation
factor 2 (EF-2) or glycerinealdehydephosphate dehydrogenase
(GAPDH). PCR reactions were performed with as few cycles as pos-
sible to detect the PCR products in ethidium bromide (0.1%)-stained
1.5% agarose gels and cDNA volumes were adjusted for consecutive
analyses by densitometry (One-Dscan Gel analysis software from
Scanalytics, Billerica, MA, USA). Programs and primers for the
measurement of steady state levels of mRNA were as follows.
A unique 2 min period for complete denaturation at 94‡C in the
beginning, followed by a primer-speci¢c number of cycles of 30 s
denaturation at 94‡C, 30 s annealing at 58‡C (CD40 54‡C, CD154
55‡C) and 1 min primer extension at 72‡C, with an additional 5 min
at 72‡C for the ¢nal extension in the end. CD40: expected size 442 bp,
26^32 cycles, sense 5P-GTGTGTTACGTGCAGTGACAA-3P, anti-
sense 5P-ATCCTCACAGCTTGTCCA 3P (corresponding to nucleo-
tide sequences 74^94 and 515^498 of the murine CD40 gene, Gen-
Bank accession number M83312); CD154: 435 bp, 26^37 cycles, sense
5P-TTTTGCTGTGTATCTTCATAG-3P, anti-sense 5P-CGTTGAC-
TCGAAGGCTCCCGA-3P (135^155 and 569^549, murine CD154
gene, X65453); EF-2: 218 bp, 19^26 cycles, sense 5P-GACATCAC-
CAAGGGTGTGCAG-3P, anti-sense 5P-GCGGTCAGCACAATGG-
CATA-3P (1990^2010 and 2207^2188, human EF-2 gene, Z11692);
GAPDH: 572 bp, 20^24 cycles, sense 5P-TCACCATCTTCCAG-
GAGCG-3P : anti-sense 5P-CTGCTTCACCACCTTCTTGA-3P (245^
263 and 816^797, rat GAPDH gene, M17701).
All PCR reactions were performed in a Hybaid OmnE thermocycler
(AWG, Heidelberg, Germany). To verify the identity of the ampli¢-
cation products with the designed primer pairs, we cloned and se-
quenced the CD40 and CD154 PCR products and found a 87 and
93% homology with the published sequences of the murine genes,
respectively.
2.3. EMSA
Nuclear extracts from the cultured raSMC were prepared essentially
as described [15] except that Igepal CA-630 (Sigma-Aldrich) was used
instead of Nonidet-P40 as a detergent. Aliquots of nuclear protein
(10 Wg) were incubated with 10^20 000 cpm of the double-stranded
(ds) oligodeoxynucleotides (ODN) in binding bu¡er [16] containing
1.33 mmol/l DTT and 1 Wg poly(d(I-C)) in a total volume of 15 Wl
for 30 min at ambient temperature. The resulting protein-DNA com-
plexes were analyzed by non-denaturing polyacrylamide gel (4%) elec-
trophoresis and autoradiography by exposing the dried gels to Kodak
X-OMAT AR X-ray ¢lm (Sigma-Aldrich). To monitor the speci¢city
of the binding reaction, supershift analyses were performed by pre-
incubation of the nuclear extracts (10 Wg protein) with 2 Wg of a
polyclonal rabbit anti-nuclear factor (NF)-UB p65 or rabbit anti-sig-
nal transducer and activator of transcription (Stat)-1K p91 antibody
(Santa Cruz Biotechnology, Heidelberg, Germany) for 1 h at ambient
temperature in a total volume of 6 Wl. The consensus ODN (Santa
Cruz Biotechnology) were labelled with 32P by using the 5P-end label-
ling kit from Amersham Pharmacia Biotech (Freiburg, Germany).
2.4. Decoy ODN technique
Ds decoy ODN were prepared from the complementary single-
stranded (ss) phosphorothioate-bonded ODN (Eurogentec, Cologne,
Germany) by melting at 95‡C for 5 min followed by a cool-down
phase of 3 h at ambient temperature. The e⁄ciency of the hybrid-
ization reaction was checked on 2.5% agarose gels containing 0.1%
ethidium bromide and usually found to exceed 80%. The ds decoy
ODN were pre-incubated with the cultured raSMC for 4^16 h at
concentrations ranging from 4 to 16 WM. Thereafter, the decoy
ODN-containing medium was replaced by fresh medium to which
the various test compounds were added. On the basis of subsequent
EMSA and RT-PCR analyses, an optimum concentration of 10 WM
and a pre-incubation period of 4 h was determined for all decoy ODN
used (not shown). The ss sequences of the decoy ODN were as follows
(underlined letters denote phosphorothioate-bonded bases): activator
protein-1 (AP-1, sense 5P-CGCTTGATGACTCAGCCGGAA-3P ;
CCAAT enhancer binding protein (C/EBP), palindrome 5P-TGCA-
GATTGCGCAATCTGCA-3P ; interferon regulatory factor-1 (IRF-
1), sense 5P-GGAAGCGAAAATGAAATTGAC-3P ; NF-UB, sense
5P-AGTTGAGGGGACTTTCCCAGG-3P ; Stat-1, sense 5P-CATGT-
TATGCATATTCCTGTAAGTG-3P.
2.5. Nuclear run-on analysis
All steps were performed at 0^4‡C. Approximately 5U106 raSMC
in 100 mm Petri dishes were exposed to interleukin-1L (IL-1L, 60 U/
ml) plus tumor necrosis factor K (TNFK, 1000 U/ml) or vehicle for 3 h.
Thereafter, the cells harvested with a cell scraper and incubated for
10 min in two volumes of lysis bu¡er (5 mM HEPES, 1 mM MgCl2,
1 mM DTT, 20% glycerol, 0.05% Triton X-100 pH 7.4) after which
time the volume was adjusted to 2 ml with cold wash bu¡er (20 mM
Tris, 20% (w/v) glycerol, 140 mM KCl, 10 mM MgCl2, 1 mM DTT,
protease inhibitor mix pH 7.4) and the cells were lysed with 15 strokes
in a EMBL cell cracker device as described [17]. The lysate was cen-
trifuged for 20 s at 300Ug and 0^4‡C in a micro-centrifuge, the pellet
discarded and the supernatant centrifuged for 5 min at 1650Ug. The
nuclear pellet was washed three times with 1 ml cold wash bu¡er,
collected by centrifugation at 1650Ug for 5 min and suspended in
approximately four volumes of reaction bu¡er (2 mM each CTP,
GTP and UTP, 3 mM ATP, 20 U/ml RNAsin (Fermentas, Vilnius,
Lithuania), 8.5 mM creatinephosphate and 0.1 mg/ml creatine kinase
(Roche Diagnostics, Mannheim, Germany) in cold wash bu¡er). Half
of the nuclei were immediately lysed in four volumes of GTC bu¡er as
the negative control and the other half was incubated for 30 min at
30‡C and then lysed. Total RNA was isolated and RT-PCR per-
formed as described before, except for the use of random primers
instead of oligo-dT primers in the reverse transcription step. When
RT-PCR with mRNA from control nuclei was performed, the amount
of cDNA synthesized was typically not detectable or amounted to
maximally 20% of that from the incubated nuclei, demonstrating
that the PCR products obtained from this procedure re£ected de
novo mRNA synthesis in the isolated nuclei.
2.6. Western blot analysis
Western blot analysis of CD40 protein expression in the raSMC
(cultured in 60 mm diameter dishes, con£uence s 80%) was essen-
tially performed as described [18] except that cell homogenates were
additionally treated for 15 min with 0.5% (w/v) CHAPS at 0^4‡C to
enrich the membrane-bound CD40 protein in the 10 000Ug superna-
tant. Positive control samples from rat thymus and spleen were pre-
pared in essentially the same manner, except that the tissue was ho-
mogenized at 0^4‡C by using a glass potter with a te£on piston.
Protein concentrations were determined by using the sodium dodecyl-
sulfate (SDS) modi¢cation of the micro-Lowry method [19]. Aliquots
of the protein extracts (10^50 Wg/lane) were separated by denaturing
polyacrylamide gel (10%) electrophoresis in the presence of SDS and
then transferred onto nitrocellulose membranes. The immobilized
CD40 protein was visualized by subsequent incubation with a poly-
clonal rabbit anti-CD40 antibody (1:2500 dilution in blocking bu¡er,
Research Diagnostics, Flanders, NJ, USA) for 2 h at ambient temper-
ature followed by a polyclonal peroxidase-conjugated anti-rabbit anti-
body (1:7500 dilution, Sigma-Aldrich) for 1 h at ambient temperature,
incubation with the Super Signal Blaze chemiluminescence reagent
according to the manufacturer’s instructions (Pierce Chemical, Rock-
ford, IL, USA) and exposure to Kodak X-OMAT AR ¢lm for up to
5 min. Thereafter, the loading and transfer of equal amounts of pro-
tein in each line was veri¢ed by staining of the protein bands on the
nitrocellulose membrane with indian ink followed by densitometry.
2.7. Statistical analysis
Unless indicated otherwise, all data in the ¢gures and text are ex-
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pressed as mean þ S.E.M. of n observations. Statistical evaluation was
performed by Student’s t-test for unpaired data with the Instat for
Windows statistics software package (GraphPad Software, San Diego,
CA, USA) and a P value6 0.05 considered statistically signi¢cant.
3. Results
3.1. CD40 and CD154 expression
In the cultured raSMC, no expression of CD154 could be
veri¢ed at the mRNA level in the absence or presence of
interferon-Q (IFNQ) plus TNFK. The same was true for vas-
cular SMC enzymatically isolated from the rat mesentery and
the endothelium intact rat aorta (i.e. native endothelial and
smooth muscle cells, Fig. 1a). Following exposure to IFNQ
plus TNFK, on the other hand, there was a distinct expression
of CD40 in the cultured SMC as well as in the aorta (Fig. 1a).
IFNQ and TNFK alone elicited only a moderate increase in
CD40 mRNA expression, but when combined, produced a
marked (Fig. 1b) and time-dependent (Fig. 1c) synergistic ef-
fect. Combination of these two cytokines also signi¢cantly
enhanced CD40 protein expression (cf. Fig. 2c). IL-1L alone
also elicited a substantial increase in CD40 mRNA expression
which was signi¢cantly more pronounced than that caused by
either IFNQ or TNFK alone. When combined with TNFK, on
the other hand, IL-1L revealed only an additive e¡ect (Fig.
1b).
3.2. Transcription factor activation
This cytokine-inducible CD40 expression was abolished by
co-incubation with actinomycin D while cycloheximide mark-
edly enhanced basal CD40 mRNA abundance (Fig. 2a). Co-
incubation with actinomycin D also abrogated the cytokine-
induced increase in CD40 protein (Fig. 2c) and subsequent
run-on analyses con¢rmed that the cytokine-induced increase
in CD40 expression in the cultured raSMC is indeed regulated
at the transcriptional level (Fig. 2b).
Therefore, cytokine-inducible transcription factor activation
in these cells was analyzed by EMSA. As the promoter region
Fig. 1. (a) Expression of CD40 (30 cycles) and CD154 (34 cycles
mRNA) in non-stimulated and TNFK (1000 U/ml) plus IFNQ (100
U/ml)-stimulated (T/IFN) cultured raSMC, cultured mesenteric
SMC (rmSMC), endothelium-intact rat aorta and rat spleen. (b) Ef-
fects of IL-1L (IL-1, 60 U/ml), IFNQ (IFN, 100 U/ml), TNFK
(TNF, 1000 U/ml), TNF plus IL-1L (T/IL-1) and TNFK plus IFNQ
(T/IFN) on CD40 mRNA expression after 24 h (expressed as multi-
ple of the level in non-stimulated cells) in cultured raSMC (n = 3^7,
*P6 0.05 versus basal). (c) Time-dependent e¡ect of TNFK plus
IFNQ on CD40 mRNA expression in cultured raSMC (n = 6^7,
*P6 0.05 versus basal).
Fig. 2. (a) E¡ects of actinomycin D (act D, 1 WM) and cyclohexi-
mide (chx, 1 WM) on CD40 mRNA expression in cultured raSMC
after 24 h under basal conditions and following stimulation with
TNFK (1000 U/ml) plus IFNQ (100 U/ml, T/IFN). The ¢gure depicts
a typical RT-PCR analysis with the relative intensities (%), as
judged by densitometry, indicated at the top. Comparable ¢ndings
were obtained in two further experiments with di¡erent batches of
raSMC. (b) PCR-based run-on analysis of the de novo expression
of CD40 and GAPDH mRNA in isolated nuclei of raSMC exposed
to 1000 U/ml TNFK plus 60 U/ml IL-1L (+) or vehicle (3) incu-
bated for 30 min or lysed immediately after the isolation (0 min).
The ¢gure depicts a typical run-on analysis, qualitatively identical
results were obtained in two further experiments with di¡erent
batches of raSMC. (c) E¡ect of actinomycin D (+act D, 1 WM) on
the TNFK (1000 U/ml) plus IFNQ (100 U/ml)-stimulated (T/IFN) in-
crease in CD40 protein abundance (expressed as percentage of the
maximal value) in cultured raSMC after 24 h (n = 4^7, *P6 0.05
versus T/IFN).
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of the rat CD40 gene has not been sequenced yet, we em-
ployed consensus ODN together with the appropriate super-
shift antibodies. In nuclear extracts of raSMC exposed to
IFNQ plus TNFK, a signi¢cant and prolonged translocation
of the p65/p50 heterodimer (RelA) of NF-UB as well as of
Stat-1 (presumably the p91/p91 homodimer, i.e. Stat-1K) to
the nucleus was detected as early as 30 min (Fig. 3, top panel).
Addition of the NF-UB inhibitor, pyrrolidine dithiocarbamate
(PDTC, 100 Wmol/l), to the raSMC 1 h prior to that of the
cytokines not only attenuated the activation of NF-UB, but
also that of Stat-1 (Fig. 3, bottom panel). In contrast, no
signi¢cant change in the activity of the transcription factors
AP-1, C/EBP and IRF-1 was observed in the presence of both
cytokines (not shown).
3.3. E¡ects of decoy ODN
To con¢rm the involvement of NF-UB and Stat-1 in cyto-
kine-inducible CD40 expression, the decoy ODN technique
was employed. Both cytokine-stimulated CD40 mRNA (Fig.
4a) and protein expression (Fig. 4b) were signi¢cantly reduced
following pre-treatment of the raSMC with an NF-UB- or
Stat-1-speci¢c decoy ODN to approximately 50% of the con-
trol value. According to EMSA, the decoy ODN used were
highly speci¢c for their target transcription factor, the abun-
dance of which was signi¢cantly reduced in nuclear extracts
prepared from decoy ODN-treated cells, while that of the
other transcription factors was not a¡ected (not shown).
Moreover, neither the consensus decoy ODN against C/
EBP nor those against AP-1 or IRF-1 had a signi¢cant e¡ect
on CD40 mRNA expression both in quiescent and cytokine-
stimulated raSMC, while both the AP-1 and the C/EBP decoy
ODN clearly attenuated the cytokine-induced expression of
other gene products in these cells (not shown). Compatible
inhibitory e¡ects of the decoy ODN for NF-UB and Stat-1
on CD40 mRNA expression were also observed with human
umbilical vein cultured endothelial cells exposed to TNFK
plus IFNQ (not shown).
4. Discussion
Due to the nature of the interaction between CD40 receptor
and ligand resulting in a trimerization of the receptor protein
[2,3], antibodies against CD40 tend to activate the CD40 sig-
nalling pathway in CD154 target cells rather than blocking it.
Antagonists for CD40 are also not yet available so that apart
from CD154-blocking antibodies, targeting of CD40 gene ex-
pression (i.e. by suppressing the activation of essential tran-
scription factors) may provide a means for interfering with the
CD40-CD154-mediated interaction of activated T-cells and
the vessel wall, a consideration that prompted us to investi-
gate in more detail cytokine-inducible CD40 gene expression
in raSMC.
With respect to the cytokines capable of inducing CD40
expression, we could con¢rm both at the mRNA and protein
Fig. 3. (Top panel) Time-dependent changes in the abundance of
NF-UB (p65/p50 heterodimer and p50/p50 homodimer) and presum-
ably the p91/p91 homodimer of Stat-1 in the nuclei of TNFK (1000
U/ml) plus IFNQ (100 U/ml)-stimulated (TNF/IFN) cultured
raSMC. The ¢gure depicts typical EMSA with the appropriate
supershift analysis performed with a single batch of raSMC. Identi-
cal ¢ndings were obtained with at least three further batches of
raSMC for each transcription factor. (Bottom panel) E¡ects of
PDTC (100 WM) on basal and TNFK plus IFNQ-stimulated (TNF/
IFN) nuclear translocation of NF-UB and Stat-1 in cultured raSMC
after a 30 min incubation. The ¢gure depicts two typical EMSA
performed with the same batch of cells. Comparable ¢ndings were
obtained for each transcription factor in at least two further experi-
ments with di¡erent batches of raSMC.
Fig. 4. (a) E¡ects of 100 WM PDTC (1 h pre-incubation) and 10 WM
each of the indicated consensus decoy ODN (4 h pre-incubation) on
TNFK (1000 U/ml) plus IFNQ (100 U/ml)-stimulated (T/IFN) CD40
mRNA expression (expressed as percentage of the maximal value)
in cultured raSMC after 6 h (n = 4^6, *P6 0.05 versus T/IFN). (b)
Original Western blot showing the e¡ect of PDTC and that of the
NF-UB and Stat-1 consensus decoy ODN on CD40 protein expres-
sion in TNF/IFN-stimulated raSMC. Experimental conditions were
as described above, except that incubations were terminated after
24 h. The relative intensities of the two CD40-speci¢c protein bands
(judged by densitometry and expressed as percentage of the maximal
level) are indicated at the top of the ¢gure. Comparable ¢ndings
were obtained in two further experiments with di¡erent batches of
raSMC.
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level previous ¢ndings in human cultured endothelial [7,8] and
smooth muscle cells [4] of an up-regulation of CD40 immu-
noreactivity following exposure to IFNQ, IL-1L, TNFK and
especially to the combination of IFNQ and TNFK. Of note
was that we routinely detected two CD40 immunoreactive
bands by Western blot analysis both in the positive control
(rat thymus) and in the cultured raSMC, a major 48 kDa
band and a minor band migrating at 45 kDa. The identity
of the second band is unclear at present, but it may represent
a di¡erently glycosylated or phosphorylated form of the mem-
brane-bound CD40 or the soluble isoform [2].
Both basal and cytokine-stimulated CD40 expression in the
cultured raSMC was either abolished or markedly attenuated
in the presence of the RNA synthesis inhibitor, actinomycin
D, hence pointing to a de novo expression of the CD40 gene,
a notion that was veri¢ed by subsequent nuclear run-on anal-
yses. Especially basal CD40 mRNA expression, on the other
hand, was markedly up-regulated following co-incubation
with the protein synthesis inhibitor, cycloheximide. While
this is often assumed to result from mRNA stabilization by
cycloheximide, another explanation is that CD40 is a primary
response gene, the expression of which is regulated by cyclo-
heximide-sensitive transcription factors. NF-UB is a prime
candidate for such a transcription factor, as its activity is
enhanced due to the fact that cycloheximide prevents the rap-
id NF-UB-induced re-synthesis of the inhibitory IUBK subunit
[20].
Prompted by this ¢nding, we analyzed ¢ve di¡erent tran-
scription factors (AP-1, C/EBP, IRF-1, NF-UB and Stat-1)
that we thought might be involved in cytokine-inducible
CD40 gene expression. These transcription factors have either
been shown previously to play an important role in the ex-
pression of other primary response genes [20^23] or were
known to be preferably activated by IFNQ [24,25]. According
to EMSA, only two transcription factors, the p65/p50 hetero-
dimer of NF-UB (RelA) and presumably the p91/p91 homo-
dimer of Stat-1 (Stat-1K), were rapidly translocated to the
nucleus of the stimulated raSMC. Interestingly, the NF-UB
inhibitor, PDTC, not only inhibited the cytokine-stimulated
translocation of NF-UB, but also that of Stat-1. Moreover,
PDTC virtually abolished the IFNQ/TNFK-induced expression
of CD40, suggesting that these two transcription factors in-
deed play a crucial role in IFNQ/TNFK-stimulated CD40 gene
expression in these cells.
To further substantiate this hypothesis, the decoy ODN
technique was employed by using the same consensus ODN
as for the EMSA but modi¢ed with phosphorothioate for
added stability. After thoroughly testing their target speci¢c-
ity, optimum concentration and pre-incubation period by
EMSA, IFNQ/TNFK-mediated CD40 mRNA and protein ex-
pression were found to be signi¢cantly down-regulated follow-
ing exposure to the decoy ODN for NF-UB and Stat-1, but
not by those directed against AP-1, C/EBP or IRF-1.
When considering the PDTC, EMSA and decoy ODN data
together, they all suggest that IFNQ via activation of Stat-1K
and TNFK via activation of NF-UB synergistically induce
CD40 gene expression in the cultured raSMC. This most
likely holds true also for CD40-expressing human cells.
Thus, a role for NF-UB in CD40 expression has recently
been proposed for Burkitt lymphoma cells stimulated with
Epstein-Barr virus latent membrane protein-1 [26]. Moreover,
the comparable inhibitory e¡ect of the NF-UB and Stat-1
decoy ODN on IFNQ/TNFK-stimulated CD40 expression in
human cultured endothelial cells (M. Hecker and A. Wagner,
unpublished observation) as well as the putative binding sites
for transcription factors that can be identi¢ed in the 5P-£ank-
ing region of the human CD40 gene also substantiate this
conclusion.
Thus far, 758 bases of the 5P-£anking region of the human
CD40 gene have been sequenced (submitted to GenBank in
1995, accession number X87626), but transcription factor
binding sites have not been analyzed in detail. We therefore
analyzed the 5P-£anking region of the human CD40 gene
again by using the MatInspector V2.2 software package [27]
and identi¢ed three NF-UB p65 binding sites at 3183, 3291
and 3587 bases and two Stat sites at 3228 and 3570 bases.
The 5P-£anking region of the human CD40 gene, however,
does not contain a classical TATA box or binding sites for
AP-1, C/EBP or IRF-1 when scanned with the appropriate
stringency and this would ¢t to the observed lack of e¡ect
of the corresponding decoy ODN on cytokine-stimulated
CD40 expression in the cultured raSMC.
What are the functional consequences of this cytokine-in-
duced increase in CD40 expression in vascular SMC? Inter-
estingly, we were unable to detect any expression of CD154
both in native and cultured SMC from the rat. This ¢nding is
at variance with a recent report stating that functional CD154
is expressed on human endothelial and smooth muscle cells
and is up-regulated by IFNQ, IL-1L or TNFK during arterio-
sclerosis [4]. We do not yet have a plausible explanation for
these con£icting data, but in our hands, both human and rat
endothelial and smooth muscle cells act as true recipients for
CD154, i.e. they do not express the ligand themselves even in
the presence of the afore-mentioned cytokines. One interesting
suggestion has been that the interaction of T-cells and vascu-
lar SMC via CD40-CD154 triggers the expression of matrix-
degrading enzymes in the SMC that promote plaque destabi-
lization or rupture [28]. In a similar context, the interaction
between CD154-expressing platelets [5] and CD40-expressing
SMC may be of relevance for restenosis after angioplasty and
poses the intriguing question whether activation of vascular
SMC via CD40 promotes apoptosis or proliferation of these
cells.
In summary, the present ¢ndings demonstrate that the
marked synergistic e¡ect of the pro-in£ammatory cytokines,
IFNQ and TNFK, on CD40 gene expression in raSMC (and
most likely also in human cultured endothelial cells) occurs at
the level of transcription and is mediated by the simultaneous
activation of NF-UB/RelA by TNFK and Stat-1K by IFNQ.
The potent suppression by the decoy ODN of Stat-1-depend-
ent CD40 expression may provide an interesting therapeutic
tool for speci¢cally interfering with CD40-CD154-mediated
chronic in£ammatory responses in vivo including arterio-
sclerosis, as both the activation of CD154-expressing T-lym-
phocytes [29,30] and the expression of CD40 in endothelial
and smooth muscle cells [4,7,8] appears to be IFNQ-depend-
ent.
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